Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AADINASDAQ:HURANASDAQ:KRRONASDAQ:NBTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAADIAadi Bioscience$1.58-1.9%$1.80$1.21▼$3.81$39.02M0.68253,454 shs87,175 shsHURATuHURA Biosciences$3.77+0.9%$3.40$1.80▼$7.93$165.11M0.53254,703 shs67,241 shsKRROKorro Bio$13.92-6.0%$18.29$11.13▼$98.00$130.68M2.6691,986 shs34,580 shsNBTXNanobiotix$3.34-1.6%$3.38$2.76▼$7.51$157.24M0.2613,232 shs11,421 shsInvesting Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAADIAadi Bioscience-6.67%+8.78%-3.01%-44.48%-19.50%HURATuHURA Biosciences-4.36%-4.85%+10.36%-16.74%+372,999,900.00%KRROKorro Bio-16.24%-11.22%+2.92%-62.14%-73.80%NBTXNanobiotix-0.81%+10.44%+8.41%+3.35%-43.91%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAADIAadi BioscienceN/AN/AN/AN/AN/AN/AN/AN/AHURATuHURA BiosciencesN/AN/AN/AN/AN/AN/AN/AN/AKRROKorro Bio1.5851 of 5 stars3.60.00.00.03.40.00.6NBTXNanobiotix1.4495 of 5 stars3.33.00.00.01.00.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAADIAadi Bioscience 2.00Hold$1.675.49% UpsideHURATuHURA Biosciences 3.25Buy$12.67236.43% UpsideKRROKorro Bio 3.25Buy$114.63723.75% UpsideNBTXNanobiotix 2.50Moderate Buy$8.00139.81% UpsideCurrent Analyst Ratings BreakdownLatest AADI, HURA, NBTX, and KRRO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/29/2025KRROKorro BioCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy4/28/2025KRROKorro BioCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$74.004/16/2025KRROKorro BioChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$25.004/4/2025NBTXNanobiotixGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$12.00 ➝ $8.004/3/2025HURATuHURA BiosciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$13.00 ➝ $12.003/20/2025KRROKorro BioHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$115.00 ➝ $115.003/19/2025KRROKorro BioRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$105.00 ➝ $95.003/3/2025HURATuHURA BiosciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$13.002/17/2025NBTXNanobiotixUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold(Data available from 5/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAADIAadi Bioscience$25.07M1.56N/AN/A$4.29 per share0.37HURATuHURA BiosciencesN/AN/AN/AN/A($4.11) per shareN/AKRROKorro Bio$2.27M57.54N/AN/A$21.19 per share0.66NBTXNanobiotix-$11.61M-13.54N/AN/A($0.04) per share-83.40Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAADIAadi Bioscience-$65.76M-$2.35N/AN/AN/A-246.06%-71.87%-57.28%N/AHURATuHURA Biosciences-$8.32MN/A0.00∞N/AN/AN/A-152.88%5/13/2025 (Estimated)KRROKorro Bio-$81.17M-$9.39N/AN/AN/AN/A-50.25%-38.48%5/13/2025 (Estimated)NBTXNanobiotix-$42.97MN/A0.00N/AN/AN/AN/AN/A5/20/2025 (Estimated)Latest AADI, HURA, NBTX, and KRRO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025N/AHURATuHURA Biosciences-$0.14N/AN/AN/AN/AN/A5/13/2025Q1 2025KRROKorro Bio-$2.60N/AN/AN/A$0.13 millionN/A3/18/2025Q4 2024AADIAadi Bioscience-$0.30-$0.67-$0.37-$0.67$7.45 million$7.24 million3/18/2025Q4 2024KRROKorro Bio-$2.33-$2.26+$0.07-$2.26N/A$2.27 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAADIAadi BioscienceN/AN/AN/AN/AN/AHURATuHURA BiosciencesN/AN/AN/AN/AN/AKRROKorro BioN/AN/AN/AN/AN/ANBTXNanobiotixN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAADIAadi BioscienceN/A4.894.54HURATuHURA BiosciencesN/A1.541.54KRROKorro BioN/A11.2311.23NBTXNanobiotixN/A1.42N/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAADIAadi Bioscience52.08%HURATuHURA Biosciences0.62%KRROKorro Bio13.18%NBTXNanobiotix38.81%Insider OwnershipCompanyInsider OwnershipAADIAadi Bioscience37.30%HURATuHURA Biosciences0.20%KRROKorro Bio5.40%NBTXNanobiotix3.45%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAADIAadi Bioscience4024.70 million15.49 millionOptionableHURATuHURA BiosciencesN/A43.68 million42.20 millionN/AKRROKorro Bio709.39 million8.86 millionNo DataNBTXNanobiotix10047.13 million45.51 millionNot OptionableAADI, HURA, NBTX, and KRRO HeadlinesRecent News About These CompaniesNanobiotix Reveals Favorable Results Of JNJ-1900 Study Pancreatic Cancer; Seeks Further EvaluationMay 5 at 8:31 AM | finanznachrichten.deNanobiotix Announces Full Results From Completed Phase 1 Study Evaluating JNJ-1900 (NBTXR3) in Pancreatic CancerMay 5 at 2:00 AM | globenewswire.comNanobiotix Announces Presentation of Full Results From Completed Phase 1 Study Evaluating JNJ-1900 (NBTXR3) in Pancreatic Cancer Followed by a Conference CallApril 30, 2025 | globenewswire.comNanobiotix (NBTX) Expected to Announce Quarterly Earnings on WednesdayApril 17, 2025 | marketbeat.comNanobiotix price target lowered to $8 from $12 at GuggenheimApril 5, 2025 | markets.businessinsider.comNanobiotix (NBTX) Gets a Hold from UBSApril 5, 2025 | markets.businessinsider.comNanobiotix S.A. (NBTX) Q4 2024 Earnings Call TranscriptApril 3, 2025 | seekingalpha.comNANOBIOTIX Provides Business Update and Reports Full Year 2024 Financial ResultsApril 2, 2025 | globenewswire.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Pfizer (PFE), Nanobiotix (NBTX) and PTC Therapeutics (PTCT)April 2, 2025 | theglobeandmail.comNANOBIOTIX to Announce Fourth Quarter and Full Year 2024 Operational and Financial Update on April 2, 2025March 31, 2025 | globenewswire.comNanobiotix reports promising NSCLC treatment study resultsMarch 29, 2025 | investing.comNanobiotix Announces First Data From the Completed Dose Escalation Part of a Phase 1 Study Evaluating NBTXR3 (JNJ-1900) as a 2L+ Therapy for Patients With Locally Advanced NSCLCMarch 27, 2025 | globenewswire.comNANOBIOTIX Announces Presentation of Data From Two Phase 1 Studies Evaluating JNJ-1900 (NBTXR3)March 21, 2025 | djournal.comNANOBIOTIX Announces Presentation of Data From Two Phase 1 Studies Evaluating JNJ-1900 (NBTXR3) at the European Lung Cancer ConferenceMarch 20, 2025 | globenewswire.comNanobiotix amends global licensing agreement with Janssen PharmaceuticaMarch 18, 2025 | markets.businessinsider.comNANOBIOTIX Strengthens Financial Position Through Amendment of Global Licensing Agreement for JNJ-1900 (NBTXR3) and Extends Cash Visibility to Mid-2026March 17, 2025 | globenewswire.comNanobiotix files $200M mixed securities shelfMarch 7, 2025 | markets.businessinsider.comNanobiotix files to sell 5.62M ordinary shares for holdersMarch 7, 2025 | markets.businessinsider.comNanobiotix downgraded to Neutral from Buy at UBSFebruary 17, 2025 | markets.businessinsider.comUBS downgrades Nanobiotix (NBTX) to a HoldFebruary 17, 2025 | markets.businessinsider.com7 Best Nanotech Penny Stocks to Invest InFebruary 14, 2025 | insidermonkey.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAADI, HURA, NBTX, and KRRO Company DescriptionsAadi Bioscience NASDAQ:AADI$1.58 -0.03 (-1.86%) As of 05/6/2025Aadi Bioscience, Inc., a biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug product candidate comprises FYARRO, a form of sirolimus protein-bound particles for injectable suspension for the treatment in adult patients with advanced unresectable or metastatic malignant PEComa. The company is also involved in evaluating FYARRO in cancers, including indications targeting specific genomic alterations that activate the mTOR pathway. Aadi Bioscience, Inc. was incorporated in 2007 and is headquartered in Pacific Palisades, California.TuHURA Biosciences NASDAQ:HURA$3.76 +0.04 (+0.94%) As of 03:29 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.TuHURA Biosciences, Inc. (NASDAQ: HURA) is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. TuHURA's lead innate immune response agonist candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. TuHURA is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda® (pembrolizumab) in first line treatment for advanced or metastatic Merkel Cell Carcinoma. In addition to its innate immune response agonist candidates, TuHURA is leveraging its Delta receptor technology to develop first-in-class bi-specific ADCs, and PDCs targeting Myeloid Derived Suppressor Cells to inhibit their immune suppressing effects on the tumor microenvironment to prevent T cell exhaustion and acquired resistance to checkpoint inhibitors and cellular therapies.Korro Bio NASDAQ:KRRO$13.92 -0.89 (-5.98%) As of 03:29 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Korro Bio, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States. Its lead product candidate is KRRO-110 which is in preclinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD). It uses its RNA editing platform, OPERA to generate differentiated RNA editing product candidates. The company is also developing programs for Parkinson's disease, Amyotrophic lateral sclerosis, severe alcohol-associated hepatitis, and other subsets of pain. Korro Bio, Inc. was founded in 2018 and is based in Cambridge, Massachusetts.Nanobiotix NASDAQ:NBTX$3.34 -0.05 (-1.59%) As of 03:23 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is headquartered in Paris, France. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Disney Stock Jumps on Earnings—Is the Magic Sustainable? AMD Relieves Market Despite Ongoing Share Price Outlook Caution Gold’s Record Run in 2025: Here Are 3 Ways to Ride the Surge What the New Quarter Says About Super Micro Computer's Future Archer Stock Eyes Q1 Earnings After UAE Updates Ford Motor Stock Rises After Earnings, But Momentum May Not Last Broadcom Stock Gets a Lift on Hyperscaler Earnings & CapEx Boost Lemonade Delivers Sweet Results, Price Reversal to Accelerate Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
